Fang Wu

19PUBLICATIONS
67CO-AUTHORS
Cross-sectional analysisCancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Dec 19, 2025
NeoADAURA: Can We Afford to Overlook Objective Response Rates?

Dan Fan, Yue Zeng, Fang Wu

|Jan 14, 2025
Optimizing the NGS-based discrimination of multiple lung cancers from the perspective of evolution.

Ziyang Wang, Xiaoqiu Yuan, Kunkun Sun

|Nov 07, 2024
Consolidation osimertinib for unresectable stage III epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer: redefining standard care.

Fang Wu, Yue Zeng, Joel W Neal

|Aug 07, 2024
Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis.

Qiaofeng Zhong, Longfeng Zhang, Lin Wu

|May 13, 2024
Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer.

Yue Zeng, Chun-Hong Hu, Yi-Zheng Li

|Jan 14, 2024
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Gen Lin, Zhijie Wang, Qian Chu

Pageof 4

Frequent Collaborators

3 joint publications

Tangfeng Lv

3 joint publications

Jisheng Li

3 joint publications

Wenzhao Zhong

3 joint publications

Chengzhi Zhou